17 September 2018 - Reimbursement reforms for antimicrobial treatments could include “a mix of milestone payments and subscription fees for developers of FDA approved products with high economic and clinical value, targeted at multi-drug resistant organisms and linked to proven clinical outcomes,” FDA Commissioner Scott Gottlieb said in a speech at Pew Charitable Trusts on Friday.
He also offered the idea of using a “subscription-based model” that could see hospitals paying a flat rate for access to a certain number of doses of a new antimicrobial.
Currently, the Centers for Disease Control and Prevention estimates that the direct cost of antimicrobial resistance on the US economy is $20 billion annually.